Retrospective Study on the Efficacy and Safety of Dulaglutide in Patients with Diabetes and Moderate-Advanced Chronic Kidney Disease

Figures & data

Table 1 Side Effects and Hypoglycemia with Dulaglutide

	Total (N=149)
Side Effects	N=28 (19% of Total)
Nausea/vomiting	16 (57%)
Diarrhea/constipation	9 (32%)
GERD	1 (4%)
Rash	1 (4%)
Pancreatitis	1 (4%)
Cholelithiasis/cholecystitis	3 (11%)
Unspecified Gl	3 (11%)
Leading to Discontinuation	N=11 (7% of Total)
Nausea/vomiting	4 (36%)
Rash	1 (9%)
Unspecified GI	2 (18%)
Cholecystectomy	3 (27%)
Pancreatitis	1 (9%)
CKD Stage
3	5 (18%)	P=0.747
4	17 (61%)
5	6 (21%)
Severity of Hypoglycemia	N=41 (28% of Total)
Level 1	11 (27%)
Level 2	13 (32%)
Level 3	1 (2%)
Unspecified	16 (39%)
Hypoglycemia by CKD Stage
3	10 (24%)	P=0.004
4	22 (54%)
5	6 (15%)
Unspecified	3 (7%)
Hypoglycemia with Dulaglutide Discontinuation	2 (5%)
Insulin or Sulfonylurea Use	40 (98%)

Abbreviations: CKD, chronic kidney disease; GERD, gastroesophageal reflux disease; GI, gastrointestinal.

Figure 1 Dulaglutide Use Improves Glycemic Control and Weight Loss after 1 year. Assessment of (A) hemoglobin A1c (n=128) (B) weight (n=131) (C) body mass index (n=131). Bars and error bars represent mean ±SEM. *P<0.05.